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Abstract
Background: Diabetes mellitus is characterized jointly by hyperglycemia and hyperinsulinemia that make insulin
more prone to be glycated and evolve insulin advanced glycation end products (Insulin- AGE). Here, we report the
effect of beta-hydroxy butyrate (BHB) (the predominant ketone body) on the formation of insulin-AGE, insulin
glycation derived liposomal lipid peroxidation and insulin-AGE toxicity in microglial cells.
Methods: The inhibitory effect of BHB was monitored as a result of insulin incubation in the presence of glucose or
fructose using AGE-dependent fluorescence, Tyr fluorescence as well as anilinonaphthalenesulfonate (ANS) andthioflavin
T (ThT) binding, and circular dichroism (CD) investigations. To study lipid peroxidation induced by insulin glycation,
thiobarbituric acid (TBA) assay and thiobarbituric acid reactive substance (TBARS) monitoring were used. The effect of
insulin–AGE on microglial viability was investigated by 3-(4, 5 dimethylthiazol-2-yl)—2, 5-diphenyltetrazoliumbromide
(MTT) cell assay and Annexin V/propidium iodide (PI) staining.
Results: Here we are reporting the inhibitory effect of BHB on insulin glycation and generation of insulin-AGE as a
possible explanation for insulin resistance. Moreover, the protective effect of BHB on consequential glycation derived
liposomal lipid peroxidation as a causative event in microglial apoptosis is reported.
Conclusion: The reduced insulin fibril formation, structural inertia to glycation involved conformational changes, anti-lipid
peroxidation effect, and increasing microglia viability indicated the protective effect of BHB that disclose insight on the
possible preventive effect of BHB on Alzheimer’s disease.
Introduction
Type 1 Diabetes is generally characterized by raised level
of blood sugar (hyperglycemia) due to imperfection in
insulin secretion, type 2 diabetes is characterized by in-
sulin resistance that results in both of hyperglycemia
and hyperinsulinemia and finally type 3 diabetes is char-
acterized with neurodegeneration linked with insulin re-
sistance. Although, increasing evidences in the literature
pointing toward strong correlation between insulin re-
sistance and Alzheimer’s disease (AD) [1, 2] but, that
correlation has not been yet formally recognized.
Under hyperglycemic condition almost all proteins are
prone to be glycated in a nonenzymatic fashion. It is
established that protein glycation, oxidative stress, and
lipid peroxidation are key processes in diabetes and re-
lated complications [3, 4]. Due to the glucose auto-
oxidation and protein glycation, hyperglycemia result in
increased production of reactive oxygen species (ROS)
that originates oxidative stress as an imbalance between
radical- generating and radical-scavenging systems [5].
Protein glycation is whereby labile Schiff base is formed
by nonenzymatic reaction between annomeric carbonyl
group of an open ring carbohydrate and amino group(s) of
the protein molecule followed by molecular rearrange-
ment to form stable Amadori products that provoke the
formation of advanced glycation end products (AGE) after
additional dehydration reaction and further molecular re-
arrangements [6]. Following the protein glycation, a series
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of events occur covering α-helix to β-sheet transform-
ation, cross β structure formation, and generation of sol-
uble amyloid prefibrils [7]. Membrane lipids are mainly
prone to oxidation by ROS owing to their polyunsaturated
fatty acid content [8]. That is why prefibriles and ROS ini-
tiate membrane involved events or damages, that conse-
quently induce apoptotic response and cell death [9].
Hence, antioxidants suppose to effectively protect against
glycation derived free radicals and considered as a thera-
peutic potential for the inhibition of ROS involved
processes [10].
Ketone bodies (KB) comprise 3-beta-hydroxybutyrate
(BHB), acetoacetate (AcAc), and acetone while the later is
the least abundant one. They are always present in the
blood and their levels increase during fasting and pro-
longed exercise [11]. They are also found in the blood of
neonates and pregnant women. However, type 1 diabetes
is the most common pathological cause of raised blood ke-
tones due to increased lipid catabolism under hypoinsuli-
nemia. In such a condition, the BHB: AcAc ratio arises
from normal, 1:1 to as high as 10:1. It has been a decade
that BHB is reported to be useful against cell apoptosis
[12], adipocyte lipolysis inhibition [13], and considered as
a treatment for various diseases including epilepsy,
Huntington’s, Parkinson’s, and Alzheimer’s [14, 15]. Con-
currency of hyperglycemia and hyperinsulinemia in type 2
diabetes, make insulin prone to be glycated. Here we are
reporting the inhibitory effect of BHB on insulin glycation
and generation of insulin advance glycation end product
(insulin-AGE) as a possible explanation for insulin resist-
ance. Moreover, the protective effect of BHB on conse-
quential glycation derived liposomal lipid peroxidation as
causative events in microglial apoptosis are reported.
Materials and methods
Material
Newborn rats (Wistar strain) were obtained from the
University of Tehran animal facilities. The Annexin-V-
FITC apoptosis assay kit was from Molecular Probes
Inc., UK. Human recombinant insulin was gifted by Exir
pharmaceutical company (Iran). Thioflavin T was from
Merck Company and other chemicals used in this study
were obtained from Sigma Aldrich (USA). All solutions
were prepared using double—distilled water.
Sample preparation
Insulin at a final concentration of 0.5 mg.ml−1 was dis-
solved in phosphate buffer (50 mM, pH 7. 4) and incu-
bated with 16.5 mM D-glucose or D-fructose in either
the presence or absence of 14.4 mM β-hydroxy butyrate
(BHB) which is close concentration in individuals with
post prolonged fasting (mM) or ketoacidosis, based on
literature [16–19]. All solution was filtered using 0.2 μm
membrane filter (Milipore, USA) under sterile condition.
All samples were incubated under physiological condi-
tions (at dark and 37 °C) for 0 to 96 h, and then stored
at −20 °C until using for further analysis.
Fluorescence measurement
The Cary Eclipse fluorescence spectrophotometer (Varian,
Australia) was used for monitoring the AGE dependent
fluorescence, the changes in the environment of the Tyr
residue in insulin and for probing the available hydropho-
bic portion of protein (ANS) and ELISA reader fluores-
cence H4 (Synergy H4, Bio Tek, USA) was used for ThT
binding analysis. Protein intrinsic (Tyr) fluorescence was
analyzed at 307 nm after excitation at 276 nm. AGE
dependent fluorescence intensity measurement of glycated
insulin in the presence or absence of BHB was carried out
at 384 nm excitation wavelength and emission spectra
were recorded in the wavelength range of 384–500 nm.
The protein concentration was 0.5 mg.ml−1.
For ANS fluorescence measurement, 200 μL from the
incubated mixtures (0.2 mg.ml−1 insulin) in the presence
or absence of BHB (14.4 mM) at 37 °C were added to
fresh solution of ANS (3 μM in 50 mM phosphate buffer
pH 7.4) and incubated for 30 min in the dark, then the
emission intensity was measured after excitation at 463 nm
at room temperature to study the kinetics of change in
solvent-exposed hydrophobic pockets due to the gener-
ation of partially folded intermediates during insulin glyca-
tion, aggregation, and AGE formation. For ThT assay
20 μL aliquots of 0.5 mg.ml−1 samples were added to
180 μL solution containing 25 μM ThT (in 50 mM phos-
phate buffer pH 7.4), then fluorescence emission was deter-
mined at 490 nm using a H4 spectrometer. Fluorescence
emission intensities were plotted against time after excita-
tion at 440 nm. The emission values of the buffer and fresh
insulin were used as background correction and control,
respectively. The averages of triplicate measurements were
used for each sample.
Circular dichroism (CD) spectroscopy
Far-UV CD was used for analyzing secondary structure
during fibrillation. The CD measurements were obtained
using a CD spectropolarimeter (J-810, Jasco, Japan) with
1-mm path length of a quartz cuvette at 25 °C and data
were scanned from 190 nm to 260 nm at 1 nm intervals.
The final protein concentration was 0.2 mg.ml−1in 50 mM
phosphate buffer pH 7.4. The bandwidth was set at 1 nm.
The spectrum of phosphate buffer was subtracted from
sample spectra for data analysis. All CD spectra converted
to mean residue ellipticity using the following relationship:
θ½  ¼ θ=10ð Þ MRM=LCð Þ
Where [θ] is ellipticity (deg.cm2.dmol−1) at wavelength
λ, θ is the observed ellipticity in millidegree, MRW is
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the mean residue weight, L is the path length (in cm),
and C is the protein concentration (mg.ml−1). The per-
centage of secondary structure was obtained using
CDNN software.
Preparation of liposome and lipid peroxidation assay
Liposomes were made using a modification of the
method of Bangham [20]. Briefly, a solution of soybean
phosphatidylcholine/cholesterol in the weight ratio of
4:1 in chloroform was dried under reduced pressure
using a rotary evaporator at <50 °C to provide a thin
homogenous film, which was placed in a desiccator for
next 24 h. The film was then dispersed in phosphate
buffer and stirred for 15 min. The mixture was sonicated
to achieve a homogeneous suspension of liposomes.
Lipid peroxidation was used as an indicator of tissue in-
jury induced by reactive oxygen species. It was measured
using the thiobarbituric acid assay (TBA) based on thio-
barbituric acid reactive substance (TBARS) monitoring.
The amount of tissue TBARS was measured by the
method described by Buege and Aust [21]. In brief,
250 μl of sample at incubation time periods (10, 30, 50,
70, and 90 h) was added to an aliquot of liposomes and
then incubated at 37 °C for 24 h. Then 50 μL of TCA
(50 %) and 100 μL of TBA (0.35 g) were added to the re-
action mixture. It absolutely was then incubated for a
quarter-hour at boiling water bath and TBARS was iden-
tified at 532 nm.
Cell culture and cell viability assay
The microglia from neocortex of newborn rats (Wistar
strain) were cultured from mixed glia cultures according
to the procedure by Giulian and Baker with some modi-
fications [22]. Briefly, the cerebellum was detached,
meninges were dissected, and brain cortex tissue was
minced in a nutrient medium. Then cells were dissoci-
ated by triturating with sterile pipettes to obtain a cell
suspension. The cell suspension from each brain was
separated into two 75 ml tissue culture flasks (Falcon) in
DMEM and 20 % FCS at 37 °C with 5 % CO2 for 24 h.
After 24 h, the medium was half changed to reach 10 %
FCS for the rest of the day. The cells were fed every
4 days with a fifty percent spent medium. After 2 weeks,
cultures contained glial cells, including rounded micro-
glial cells mostly localized on the top of the monolayer.
The loosely adherent microglial cells were recovered by
gentle shaking by hand for 2 min. The cell suspension
was then cultured on 96 multiwell plates at a density of
3 × 104 cell/cm2, in 10 % FCS supplemented DMEM
medium (total volume 200 μl) for 24 h, to enter the
ramified phase. To treat the cells, the culture medium
was replaced with the insulin (6.25, 12.5, 25, 50, 75,125,
200, and 375 μg/ml, the final concentration of the gly-
cated insulin was determined according to the final
volume of 200 μl) which was glycated in the presence or
absence of BHB for a series of incubation time (0, 10, 30,
50, 70, and 90 h). Treated cells were kept in this medium
for 24 h, after which the effect of AGE on the viability of
the cells was evaluated via the MTT assay [23]. This assay
measures the mitochondrial function and is most fre-
quently used to detect loss of cell viability [24]. Neverthe-
less, this assay can underestimate the cell death because it
works best to detect the later stages of apoptosis when the
metabolic activity of the cells is strictly reduced [25]. The
treated cultured cells were incubated with 10 % of MTT
per well for four hours (from the stock solution of
5 mg.ml−1 of MTT in PBS, which was filtered through
0.2 μm syringe filter and kept all the time in dark condi-
tion), after which the whole media were replaced with
100 μl DMS solution to dissolve the MTT formazan crys-
tals. The optical density (OD) at 580 nm was determined
using an EIA Multiscan MS micro-plate reader.
Cell survival was calculated as a percentage by dividing
the absorbance values of the experimental group (treated
cells) by the absorbance values of the control group (un-
treated cells). Each assay was repeated six times, to ensure
the reproducibility of the results. Moreover, apoptosis ana-
lysis was performed using Annexin V-FITC and propi-
dium iodide (PI) dual staining according to the
manufacturer’s instructions. Briefly after a period of treat-
ment, cells were harvested and washed in cold phosphate-
buffered saline (PBS) followed by centrifugation at 900 × g
for 10 min. The pellet re-suspend in 200 μL annexin bind-
ing buffer to prepare a cell density of 1 × 106 cell.ml−1.
Then 5 μl of Alexa Fluor 488 annexin V and 5 μl of the
50 μg.ml−1 propidium iodide (PI) solutions was added.
After 15 min incubation at room temperature, 300 μl of
1× annexin binding buffer was added and samples were
kept on ice. Then the cells were analyzed by flowcyto-
metry, measuring the fluorescence emission at 530 nm
(e.g. FL1) and 575 nm (e.g. FL2). After staining apop-
totic, necrotic and live cells show green, red and no
fluorescence, respectively [26]. All procedures were per-
formed in accordance with institutional guidelines for
animal care and use, which adhered to the international
principles of Laboratory Animal Care (NIH publication
#85-23, revised in 1985).
Statistical analysis
Data were expressed as mean ± SD. static analysis be-
tween treatments was made using one-way ANOVA
(analysis of variance) followed by Duncan’s new multiple
range tests for multiple comparisons. P-value <0.01 was
considered statistically significant.
Results
Intrinsic and extrinsic fluorescence analysis Conform-
ational change, the formation of glycation products, and
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increasing surface hydrophobicity of insulin alone as a
control, insulin in the presence of Glc or Fru and in the
presence or absence of BHB were examined using intrin-
sic tyrosine (excitation at 280 nm), AGE-dependent (ex-
citation at 384 nm), and ANS-binding fluorescence
(excitation at 460 nm), respectively (Fig. 1). Fig. 1a
illustrates increase in the intensity of AGE-dependent
fluorescence (λex 370 nm;λem425 nm) to detect the for-
mation of AGE [27] upon glycation by Glc or Fru also
the inhibitory effect of BHB has been presented. The
kinetics of Tyr fluorescence of insulin under glycation in
the presence of Glc or Fru and presence or absence of
Fig. 1 The kinetics of changes in the fluorescence of glycated insulin in the presence or absence of BHB. a AGE-related auto-fluorescence of
insulin and modified insulin (Ins + Glc, Ins + Glc + BHB, Ins + Fru, Ins + Fru + BHB) was monitored in emission wavelength range of 384–500 nm.
After excitation at 370 nm. Insulin, glucose, fructose and BHB were alone used as a control. b Changes in the intrinsic fluorescence (λex 276 nm;
λem 307 nm) of insulin incubated with Glc or Fru in the presence or absence of BHB (c) Extrinsic ANS fluorescence, was used to assess the
change in surface hydrophobicity of insulin. Aliquots of the incubated insulin were added to 3 μM ANS and the spectra recorded after 30 min.
The excitation was performed at 350 nm and fluorescence spectra were obtained from 405 nm to 550 nm. d The β-sheet content of insulin was
determined with Thiflavin T fluorescence. Excitation and emission wavelength was 450 nm and 490 nm respectively
Sabokdast et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:42 Page 4 of 9
BHB has been depicted in Fig. 1b. Fluorescence at 280 nm
region is commonly used to study conformational alter-
ations of a protein in solution [28]. The intrinsic fluores-
cence of insulin decreased markedly during incubation
with glucose or fructose that was diminished by BHB
which indicates an inhibitory effect of BHB on glycation-
induced insulin conformation change (Fig. 1b). ANS fluor-
escence was employed to study the kinetics of change in
solvent exposed hydrophobic pockets of insulin in the
presence of insulin and Glc or Fru and presence or ab-
sence of BHB to characterize partially folded intermediates
during insulin glycation, aggregation, and AGE formation
(Fig. 1c). The fluorescence intensity enhancement of ANS
in glycated insulin with glucose or fructose indicates the
increase in solvent-exposed hydrophobic regions, originat-
ing from partially folded intermediates. BHB was approved
to decrease glycation-involved ANS fluorescence.
Thioflavin T fluorescence test resulted less β-sheet
content in the samples glycated by Glc or Fru in the
presence of BHB than the samples in the absence of
BHB (Fig. 1d).
Circular dichroism (CD) analysis
Figure 2 represents glycation-induced insulin secondary
structure transformation by Glc (2a) or Fru (2b), using
circular dichroism (CD) for the products of 72 h incuba-
tion; inhibitory effect of BHB was also included. Glyca-
tion by Glc or Fru brings about 9.7 and 15.1 percent
decrease in α-conformation, respectively. BHB not only
inhibited all, 7.9 % decreasing in α-conformation due to
glycation by Glc, but also caused even 0.9 % increasing
of this conformation for insulin incubated alone for 72 h
(BHB treatment similarly diminished increase in β-
conformation from 3.82 % to 0.2 %). Under glycation by
Fru, BHB diminished α-decrease or β-increase from
13.3 % to 6.7 % and 8.12 % to 2.8 %, respectively
(Table 1). These results support a protective effect of
BHB against glycation-induced sheet formation,
proceeding less fibril formation, and indicates on a
structural inertia to glycation induced conformational
changes due to the BHB.
Lipid peroxidation analysis
In order to investigate the preventive effect of BHB on
lipid peroxidation potential, TBARs assay was per-
formed. Figure 3 shows the level of lipid peroxidation
marker, malondialdehyde (MDA) at 532 nm as a func-
tion of time. The level of MDA as an end product of
lipid peroxidation was markedly increased in the pres-
ence of insulin glycation by glucose or fructose that was
Fig. 2 3-β hydroxybutyrate (BHB) inhibits the secondary structure change in glycated protein. a The secondary structure percentage of insulin
and modified insulin (Ins + Glc, Ins + Glc + BHB) in 50 mM sodium phosphate buffer pH 7.4 containing 0.1 mM sodium azide incubated at 37 °C
for 72 h. b CD spectra of insulin glycated with fructose in the presence or absence of BHB
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effectively inhibited by BHB (Fig. 3), most probably or as
a reason of preventive effect of BHB on insulin glycation
or pertained antioxidative property.
Microglial cell survival assay
Random images were obtained and semi-confluent rami-
fied microglial culture was observed to confirm the right
phenotype of the isolated cells. The effect of insulin-
AGEs as the products of insulin glycation by glucose or
fructose on rat microglial viability was studied using
MTT assay according to the conventional protocols with
at least 5 repeats [23]. As shown in Fig. 4a, when culture
medium was replaced with medium supplemented with
products of insulin glycation in the absence of BHB for
different period of time (0, 10, 30, 50, 70 and 90 h), the
cell viability was dramatically affected by the presence of
insulin–AGEs and as depicted, fructation derived
insulin-AGEs were 1.4–1.8 folds more effective than the
glycation products of Glc on decreasing cell viability in
the absence of BHB (Fig. 4a). However, in the presence
of BHB the cell viability was improved at more than 1.5
folds. Besides, the indices of rat microglial apoptosis
were determined using Annexin V/PI staining [29]. The
flow cytometry (FACS) analysis was carried out on
microglial cells that were treated with glycated insulin
for 72 h in the presence or absence of BHB against cor-
responding control (Fig. 4b). The percentage of cell
apoptosis were significantly increased when microglial
culture was treated with insulin glycation products, es-
pecially by fructose BHB decreased apoptotic cells about
5.3 and 8.2 folds corresponding to the cells treated with
glycation products of glucose or fructose, respectively.
Discussion
Nowadays, protein aggregation diseases such as
Alzheimer’s, Parkinson’s, cataract, mad cow diseases and
physiological aging have attained particular attention.
Moreover, protein aggregation turns out to play a signifi-
cant role in cancer i.e. p53 aggregation (as an important
tumor suppressor protein) leads to uncontrolled cell
growth [30]. One of the causative conditions in protein
aggregation known to be protein glycation [31] which not
only makes friend proteins disabilities, but also makes
them toxic and foe. In protein glycation after a nonenzy-
matic reaction between reducing sugars and protein, a
series of glycation products are consecutively generated,
including soluble prefibriles and non-soluble fibrils that
are collectively called advance glycated end products or
AGEs. Considerable evidences indicate that under
Table 1 The relative percentages of the secondary structures were estimated using the CDNN CD spectra deconvolution software.
The results are expressed as mean ± S.D. from three independent experiments
Sample α-Helix β-Sheet β-Sheet β-Turn Random-coil
Ins 0 h 39.2 ± 0.2 5.8 ± 0.05 7.7 ± 0.03 15.5 ± 0.0 31.4 ± 0.06
Ins 72 h 37.4 ± 0.1 6 ± 0.1 8 ± 0.03 15.5 ± 0.09 32.7 ± 0.3
Ins + Glc 72 h 29.5 ± 0.2 8.42 ± 0.1 9.4 ± 0.05 16 ± 0.03 36.4 ± 0.1
Ins + Fru 72 h 24.1 ± 0.05 10.5 ± 0.3 11.7 ± 0.5 16.7 ± 0.3 38.1 ± 0.9
Ins + BHB 72 h 36.3 ± 0.1 732 ± 0.2 8.1 ± 0.2 16.1 ± 0.1 32.0 ± 0.08
Ins + Glc + BHB 72 h 38.3 ± 0.1 5.9 ± 0.1 7.8 ± 0.03 15.5 ± 0.05 32.0 ± 0.08
Ins + Fru + BHB 72 h 30.7 ± 0.08 7.6 ± 0.8 9.2 ± 0.03 15.7 ± 0.03 36.5 ± 0.08
Fig. 3 The liposomal lipid peroxidation derived by insulin glycation
and reduced by BHB. It was measured using TBA assay based on
MDA and TBARS monitoring. MDA formation was determined at
532 nm against the time of incubation of glycated insulin by Glc or
Fru in the presence or absence of BHB. Results are expressed as
mean ± S.D. from three independent experiments
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hyperglycemia, protein glycation and AGE generation are
important determinants of complications often observed
in type 1 and type 2 diabetes, including nephropathy, ret-
inopathy, neuropathy and cardiovascular disease (CVD)
[32]. Although, almost all proteins could be targets for gly-
cation, but more specifically, concurrency of hypergly-
cemia and hyperinsulinemia in type 2 diabetes makes
insulin prone to be glycated to generate ROS and produce
insulin-AGEs. Insulin is glycated even in the pancreas
which has been considered in the pancreas of various ani-
mal models of type 2 diabetes [33, 34]. Prevention of pro-
tein glycation and its consecutive symptoms are of great
importance. We are reporting the inhibitory effect of BHB
on insulin-AGE formation and insulin-AGE toxicity in
microglial cells. When insulin was incubated in the pres-
ence of glucose or fructose, insulin was glycated and
AGE-dependent fluorescence was increased by the time,
followed by a protein conformational change monitored
by decreasing Tyr or increasing ANS fluorescence in-
tensities; while BHB inhibited all three mentioned
cases. Since most AGEs (such as N-carboxymethyl ly-
sine; CML and N-carboxyethyl lysine; CEL, and cross
links such as pentosidine, methylglyoxal lysine dimmer;
MOLD, and threosidine) have a characteristic fluores-
cence, with an excitation maximum at 360, and
emission around 460 nm, detection through fluores-
cence spectroscopy is a widely available method.
Insulin-AGEs formation and inhibitory effect of BHB
were collectively monitored using AGEs fluorescence
(ex360 nm, em460 nm) as a result of insulin incubation
in the presence of Glc or Fru in Fig. 1a. Insulin has
three glycation prone positions, the N-terminals of
both chains (Gly1 and Phe1) and residue Lys29 of B-
chain. As a result, three forms of insulin glycation
products have been reported (mono, di, and tri-
glycated forms) [35]. Most probably, the effect of BHB
on preventing insulin glycation is due to BHB binding
to glycation prone residues in protein to diminish the
glycation susceptibility. In addition, proteins present
their intrinsic fluorescence because of their main flour-
ophore residues; tryptophan (Trp, W), tyrosine (Tyr, Y)
and phenylalanine (Phe, F), but only Trp and Tyr are
used experimentally because their quantum yields are
high enough to give a good fluorescence signal [36]. In
insulin as a special case, Tyr dominates the fluores-
cence excitation at 280 nm in the absence of Trp. It has
been found that insulin denaturation results in (or
brought about) a decrease in Tyr fluorescence, suggest-
ing that in insulin, Tyr residues were translocated from
hydrophobic pockets to the aqueous environment and
Fig. 4 β-hydroxybutyrate (BHB) reduced cytotoxicity of glycated proteins on microglial cells. a Cell viability measured by MTT assay. Insulin alone
or incubated with Glc or Fru in the presence or absence of BHB at 37 °C for 10, 30, 50, 70, and 90 h, were added to microglial cells for 24 h. Cell
viability was measured using MTT assay and absorbance of the solutions was measured at 540 nm. Results are expressed as mean ± S.D. from five
independent experiments, (b) Microglial cells were treated for 24 h with 72 h glycated insulin glycated in the presence or absence of BHB. In
controls, insulin was incubated without Glc or Fru, in the presence or absence of BHB. The rate of apoptosis of treated microglia was detected by
Annexin-V apoptosis Assay kit and analyzed by flow cytometry. Results are expressed as mean ± S.D. from three independent experiments.
Treatments with different letters at the top of the bars are significantly different from each other according to analysis of variance (P < 0.01)
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were effectively quenched [37]. As a result of glycation
process over the period of 96 h, further fluorescence
quenching was observed when insulin was incubated in
the presence of Glc and far more in the presence of
Fru. Such conformational changes were also monitored
using ANS fluorescence (Fig. 1c). The presence of BHB
interestingly and successfully protected insulin against
glycation-involved conformational changes. Insulin
glycation ended in protein fibrillation that exhibited
increased β-sheets (Fig. 1d) and decreased α-
conformation (and increased β-conformation) (Fig. 2)
relative to the non-glycated and non-fibrillar form
reporting by CD analysis and ThT binding fluores-
cence, respectively. The CD is a powerful tool for inves-
tigating glycation dependent α- to β-conformational
changes in proteins [38]. However, ThT can bind to β-
sheets due to its geometric fitness [39], stochiometri-
cally emits after excitation at 440 nm. As expected, Fru
changed secondary structure and developed β-sheet
more effectively than the Glc; however, the preventive
effect of BHB was observed in both cases. Glycation has
reported to cause a decrease in α-helix content in various
proteins, e.g. human serum albumin (HSA) [40], bovine
serum albumin (BSA) [41], and hemoglobin (Hb) [42].
More recently, we observed that BHB can preserve the
secondary structure of HSA against Glc using CD [43].
Interestingly, BHB not only prevents glycation—derived
sheet development, but also presents a stabilizing effect
on insulin in the absence of Glc or Fru (Fig. 1d). Our re-
sults show that insulin-AGEs induce liposomal lipid per-
oxidation in a time dependent manner, nonetheless, BHB
can effectively reduce these effects (Fig. 3). The relation-
ship between the level of glycated hemoglobin and lipid
peroxidation in erythrocytes of both diabetic and healthy
subjects have been reported [44] and higher lipid peroxi-
dation in seminal plasma of diabetic than non-diabetic
subjects has been reported [45]. We assume that insulin
glycation not only can explain insulin resistance, but also
can play a role in cell death through lipid peroxidation
more importantly glial cells. Also, we are reporting the
anti-lipid peroxidation effect of BHB that can explain its
protection on microglial apoptosis. To continue, the ef-
fects of products of insulin glycation by glucose or fruc-
tose on rat microglial survival as well as the protective
effect of BHB on microglial cells were estimated using
MTT assay and flow cytometry using Annexin V/PI
staining.
These observations confirmed the cytotoxic effects of
insulin glycation products, especially by fructose, on
microglial cells (Fig. 4). Since microglia are implicated in
cascades causing neuronal loss and cognitive decline in
Alzheimer’s disease (AD), insulin–AGEs formation, es-
pecially in type 2 diabetes, are most probably involved in
AD that is proposed as type 3 diabetes. However, BHB
diminished the extent of toxicity evolved by insulin gly-
cation on microglial cells or probably inhibited micro-
glial cell apoptosis. Shan Chenga et al. has reported
preventive effect of BHB on apoptotic and necrotic cell
death by serving as a metabolic fuel for cells [46]. Be-
cause of the fact that BHB can cross the blood brain bar-
rier (BBB), arriving at neurons and glial cells [47], the
inhibitory effect of BHB on insulin-glycation, insulin-
AGEs formation, and insulin-AGEs derived liposomal
lipid peroxidation are collectively offer a possible explan-
ation on protective effect of BHB on microglial apoptosis
under diabetic condition.
Conclusion
Insulin glycation by Glc and more effectively by Fru re-
sults in insulin-AGEs formation and lipid peroxidation
that may involve in insulin resistance. Moreover, the toxic
effect of insulin-AGEs on cultured microlia are reported
in which, the glycation product of insulin by Fru presented
more toxic effect than glycation product of insulin by Glc.
Microglial apoptosis may involved in neurodegenerative
diseases such as AD. The observed protective effects of
BHB in insulin glycation and insulin-AGEs induced
microglial apoptosis, disclose the new insights of BHB ac-
tion against type 3 diabetes or AD.
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